share_log

Allarity Therapeutics | 8-K/A: Current report (Amendment)

Allarity Therapeutics | 8-K/A: Current report (Amendment)

Allarity Therapeutics | 8-K/A：重大事件(修正)
美股SEC公告 ·  09/10 09:18

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. has filed an amendment to its original Form 8-K, correcting the effective time of a reverse stock split to 12:01 a.m. Eastern Time on September 11, 2024. The amendment, filed with the SEC, includes a Certificate of Correction as Exhibit 3.3. Additionally, at the Annual Meeting held on September 3, 2024, stockholders approved several key proposals. These included an increase in the number of shares authorized for grant under the company's 2021 Equity Incentive Plan, amendments to the company's Certificate of Incorporation to decrease the number of authorized shares, and the implementation of a 1-for-30 reverse stock split of the company's common stock. The reverse stock split will result in every 30 shares of issued and outstanding common stock being combined...Show More
Allarity Therapeutics, Inc. has filed an amendment to its original Form 8-K, correcting the effective time of a reverse stock split to 12:01 a.m. Eastern Time on September 11, 2024. The amendment, filed with the SEC, includes a Certificate of Correction as Exhibit 3.3. Additionally, at the Annual Meeting held on September 3, 2024, stockholders approved several key proposals. These included an increase in the number of shares authorized for grant under the company's 2021 Equity Incentive Plan, amendments to the company's Certificate of Incorporation to decrease the number of authorized shares, and the implementation of a 1-for-30 reverse stock split of the company's common stock. The reverse stock split will result in every 30 shares of issued and outstanding common stock being combined into one share, with no fractional shares to be issued. Adjustments will be made to the per share exercise price and the number of shares purchasable upon exercise of outstanding stock options. The common stock will begin trading on a reverse stock split-adjusted basis on the Nasdaq Capital Market on September 11, 2024, under the same trading symbol 'ALLR' and a new CUSIP number.
Allarity Therapeutics, Inc.已向其原始8-K表格提交了修正，更正了逆向股票拆分的生效时间为2024年9月11日美国东部时间凌晨12:01。该修正案已向美国证券交易委员会（SEC）提交，并包括一份作为附件3.3的更正证明书。此外，在2024年9月3日举行的年度股东大会上，股东批准了几项重要提案。其中包括在公司的2021年股权激励计划下增加授予的授权股份数量、对公司的公司章程进行修正以减少授权股份数量，以及实施公司普通股每30股逆向股票拆分的1:30比例。逆向股票拆分将导致每30股已发行和持有的普通股合并为1股，并不发行碎股。对于未行使的期权，每股行权价格和可行权股数将进行调整。2024年9月11日，普通股将在纳斯达克资本市场上以逆向股票拆分调整的价格开始交易，交易标的代码仍为'ALLR'，但有一个新的CUSIP编号。
Allarity Therapeutics, Inc.已向其原始8-K表格提交了修正，更正了逆向股票拆分的生效时间为2024年9月11日美国东部时间凌晨12:01。该修正案已向美国证券交易委员会（SEC）提交，并包括一份作为附件3.3的更正证明书。此外，在2024年9月3日举行的年度股东大会上，股东批准了几项重要提案。其中包括在公司的2021年股权激励计划下增加授予的授权股份数量、对公司的公司章程进行修正以减少授权股份数量，以及实施公司普通股每30股逆向股票拆分的1:30比例。逆向股票拆分将导致每30股已发行和持有的普通股合并为1股，并不发行碎股。对于未行使的期权，每股行权价格和可行权股数将进行调整。2024年9月11日，普通股将在纳斯达克资本市场上以逆向股票拆分调整的价格开始交易，交易标的代码仍为'ALLR'，但有一个新的CUSIP编号。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间